{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:11:56Z","timestamp":1774555916374,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National High Technology Research and Development Program of China","award":["2014AA020610"],"award-info":[{"award-number":["2014AA020610"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81771489"],"award-info":[{"award-number":["81771489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science & Technology Commission","award":["Z171100000117002"],"award-info":[{"award-number":["Z171100000117002"]}]},{"name":"China National Key Research and Development Program","award":["2017YFC0908300"],"award-info":[{"award-number":["2017YFC0908300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-019-2103-0","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:07Z","timestamp":1572468247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma"],"prefix":"10.1186","volume":"17","author":[{"given":"Haibo","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhou","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sida","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11102-010-0253-4","volume":"14","author":"BD McDowell","year":"2011","unstructured":"McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA. Demographic differences in incidence for pituitary adenoma. Pituitary. 2011;14:23\u201330.","journal-title":"Pituitary"},{"key":"2103_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrendo.2014.181","volume":"11","author":"AL Lecoq","year":"2015","unstructured":"Lecoq AL, Kamenicky P, Guiochon-Mantel A, Chanson P. Genetic mutations in sporadic pituitary adenomas\u2013what to screen for? Nat Rev Endocrinol. 2015;11:43\u201354.","journal-title":"Nat Rev Endocrinol"},{"key":"2103_CR3","doi-asserted-by":"publisher","first-page":"rjx039","DOI":"10.1093\/jscr\/rjx039","volume":"2017","author":"A Amirjamshidi","year":"2017","unstructured":"Amirjamshidi A, Mortazavi SA, Shirani M, Saeedinia S, Hanif H. Coexisting pituitary adenoma and suprasellar meningioma-a coincidence or causation effect: report of two cases and review of the literature. J Surg Case Rep. 2017;2017:rjx039.","journal-title":"J Surg Case Rep"},{"key":"2103_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.endonu.2015.03.003","volume":"62","author":"F Ruiz-Juretschke","year":"2015","unstructured":"Ruiz-Juretschke F, Iza B, Scola-Pliego E, Poletti D, Salinero E. Coincidental pituitary adenoma and planum sphenoidale meningioma mimicking a single tumor. Endocrinol Nutr. 2015;62:292\u20134.","journal-title":"Endocrinol Nutr"},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00165649","volume":"29","author":"M Bondy","year":"1996","unstructured":"Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996;29:197\u2013205.","journal-title":"J Neurooncol"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-007-0011-4","volume":"10","author":"L Curto","year":"2007","unstructured":"Curto L, Squadrito S, Almoto B, Longo M, Granata F, Salpietro F, Torre ML, Marini F, Trimarchi F, Cannavo S. MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case. Pituitary. 2007;10:299\u2013305.","journal-title":"Pituitary"},{"key":"2103_CR7","first-page":"2390797","volume":"2017","author":"A Herrero-Ruiz","year":"2017","unstructured":"Herrero-Ruiz A, Villanueva-Alvarado HS, Corrales-Hernandez JJ, Higueruela-Minguez C, Feito-Perez J, Recio-Cordova JM. Coexistence of GH-producing pituitary macroadenoma and meningioma in a patient with multiple endocrine neoplasia type 1 with hyperglycemia and ketosis as first clinical sign. Case Rep Endocrinol. 2017;2017:2390797.","journal-title":"Case Rep Endocrinol"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cancergen.2015.12.002","volume":"209","author":"P Concolino","year":"2016","unstructured":"Concolino P, Costella A, Capoluongo E. Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years. Cancer Genet. 2016;209:36\u201341.","journal-title":"Cancer Genet"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"T119","DOI":"10.1530\/ERC-17-0199","volume":"24","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK. The future: genetics advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer. 2017;24:T119\u201334.","journal-title":"Endocr Relat Cancer"},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1530\/ERC-17-0346","volume":"24","author":"F Weber","year":"2017","unstructured":"Weber F, Mulligan LM. Happy 20th anniversary MEN1: from positional cloning to gene function restoration. Endocr Relat Cancer. 2017;24:E7\u201311.","journal-title":"Endocr Relat Cancer"},{"key":"2103_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1078-0432.CCR-0938-3","volume":"10","author":"B Asgharian","year":"2004","unstructured":"Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer A, Zhuang Z, Venzon DJ, Gibril F, Jensen RT. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res. 2004;10:869\u201380.","journal-title":"Clin Cancer Res"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"E142","DOI":"10.3390\/md14080142","volume":"14","author":"YJ Wu","year":"2016","unstructured":"Wu YJ, Wong BS, Yea SH, Lu CI, Weng SH. Sinularin induces apoptosis through mitochondria dysfunction and inactivation of the pI3K\/Akt\/mTOR pathway in gastric carcinoma cells. Mar Drugs. 2016;14:E142.","journal-title":"Mar Drugs"},{"key":"2103_CR13","doi-asserted-by":"crossref","first-page":"50476","DOI":"10.18632\/oncotarget.9919","volume":"8","author":"S Chen","year":"2017","unstructured":"Chen S, Fisher RC, Signs S, Molina LA, Shenoy AK, Lopez MC, Baker HV, Koomen JM, Chen Y, Gittleman H, et al. Inhibition of PI3K\/Akt\/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget. 2017;8:50476\u201388.","journal-title":"Oncotarget"},{"key":"2103_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/neuonc\/nou164","volume":"17","author":"D Pachow","year":"2015","unstructured":"Pachow D, Wick W, Gutmann DH, Mawrin C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol. 2015;17:189\u201399.","journal-title":"Neuro Oncol"},{"key":"2103_CR15","first-page":"4585","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Li C, Wang J, Song G, Zhao Z, Wang H, Wang W, Li H, Li Z, Miao Y, et al. Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq. Oncotarget. 2017;8:4585\u2013606.","journal-title":"Oncotarget"},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res. 2013;19:1180\u20139.","journal-title":"Clin Cancer Res"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.20201","volume":"56","author":"EI Surace","year":"2004","unstructured":"Surace EI, Lusis E, Haipek CA, Gutmann DH. Functional significance of S6K overexpression in meningioma progression. Ann Neurol. 2004;56:295\u20138.","journal-title":"Ann Neurol"},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29:4250\u201361.","journal-title":"Mol Cell Biol"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1210\/edrv.21.3.0399","volume":"21","author":"HM Khandwala","year":"2000","unstructured":"Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215\u201344.","journal-title":"Endocr Rev"},{"key":"2103_CR20","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1113\/jphysiol.2009.173609","volume":"587","author":"TK O\u2019Neil","year":"2009","unstructured":"O\u2019Neil TK, Duffy LR, Frey JW, Hornberger TA. The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol. 2009;587:3691\u2013701.","journal-title":"J Physiol"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4161\/cc.2.4.433","volume":"2","author":"J Liang","year":"2003","unstructured":"Liang J, Slingerland JM. Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2:339\u201345.","journal-title":"Cell Cycle"},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1530\/JOE-17-0560","volume":"236","author":"A Mafficini","year":"2018","unstructured":"Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. J Endocrinol. 2018;236:R161\u20137.","journal-title":"J Endocrinol"},{"key":"2103_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594\u2013601.","journal-title":"Nat Med"},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/not247","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, et al. Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014;16:567\u201378.","journal-title":"Neuro Oncol"},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nos264","volume":"14","author":"EQ Lee","year":"2012","unstructured":"Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, et al. Phase I\/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012;14:1511\u20138.","journal-title":"Neuro Oncol"},{"key":"2103_CR26","first-page":"1657","volume":"33","author":"U Lassen","year":"2013","unstructured":"Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013;33:1657\u201360.","journal-title":"Anticancer Res"},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125\u201332.","journal-title":"Lancet"},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801\u201311.","journal-title":"N Engl J Med"},{"key":"2103_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490\u20138.","journal-title":"Ann Neurol"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","volume":"70","author":"V Cerovac","year":"2010","unstructured":"Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 2010;70:666\u201374.","journal-title":"Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2103-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:31:28Z","timestamp":1603845088000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2103-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the medical ethics committee of Beijing Tiantan Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors in this paper consent to publication of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}